Investments, Funding & Disinvestment

The project aims to strengthen medical education while helping Sri Lanka train more healthcare professionals to meet growing national demand.

The agreement was announced during the BIO International Convention 2026 in San Diego, California, and is expected to strengthen corneal transplantation services while improving access to sight-restoring care across the UAE and the wider region.

Under the collaboration, Insilico Medicine will use its proprietary Pharma.AI platform to identify and optimise drug candidates that meet predefined scientific and early development criteria.

Under the new arrangement, Remgro now owns 100% of Mediclinic’s Southern African operations through Mediclinic International, while IHL has taken full ownership of the Swiss-based Hirslanden Group.

The Jasper, Indiana-based electronics and medical contract manufacturer will add Helvoet’s facilities in Tilburg, the Netherlands, and in Pune, India, to its global manufacturing network.

Under the agreement, QuantumCell will obtain global rights to AlzeCure’s NeuroRestore platform, including its lead drug candidate, ACD856.

The new site will serve as the company’s U.S. global headquarters and future manufacturing centre as it accelerates the development of targeted cancer therapies.

Unlike previous Ebola epidemics caused by the Zaire strain, the current Bundibugyo outbreak has no licensed vaccine or approved treatment, making research an urgent public health priority.

Biogen has paused or discontinued funding for most of Apellis’ legacy research portfolio while conducting a comprehensive review of the acquired company’s clinical and preclinical assets.

The acquisition gives Zymeworks access to Yupelri, an FDA-approved, once-daily nebulized maintenance therapy for chronic obstructive pulmonary disease (COPD) that Theravance markets in partnership with Viatris.